Xilio Therapeutics Inc
NASDAQ:XLO
Operating Margin
Xilio Therapeutics Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | US |
Market Cap | 38.8m USD |
Operating Margin | N/A |
Country | US |
Market Cap | 277.3B USD |
Operating Margin |
29%
|
Country | US |
Market Cap | 164.1B USD |
Operating Margin |
24%
|
Country | US |
Market Cap | 118B USD |
Operating Margin |
41%
|
Country | US |
Market Cap | 108.5B USD |
Operating Margin |
30%
|
Country | AU |
Market Cap | 135.7B AUD |
Operating Margin |
26%
|
Country | US |
Market Cap | 81.8B USD |
Operating Margin |
32%
|
Country | US |
Market Cap | 63.8B USD |
Operating Margin |
-100%
|
Country | US |
Market Cap | 43.1B USD |
Operating Margin |
-33%
|
Country | US |
Market Cap | 31.7B USD |
Operating Margin |
22%
|
Country | KR |
Market Cap | 37.3T KRW |
Operating Margin |
21%
|
Profitability Report
View the profitability report to see the full profitability analysis for Xilio Therapeutics Inc.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Xilio Therapeutics Inc's most recent financial statements, the company has Operating Margin of 0%.